Quote | Clarus Therapeutics Holdings Inc. Warrant 9/9/2026 (NASDAQ:CRXTW)
Last: | $0.0136 |
---|---|
Change Percent: | -77.33% |
Open: | $0.019 |
Close: | $0.06 |
High: | $0.0211 |
Low: | $0.0112 |
Volume: | 435,910 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Clarus Therapeutics Holdings Inc. Warrant 9/9/2026 (NASDAQ:CRXTW)
NORTHBROOK, Ill., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that it, together with its wholly-owned subsidiary ...
Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million Second quarter 2022 total prescription growth for JATENZO® increased 23% sequentially and increased 72% year-over-year Immediate reduction in workforce by approximately 40% of total headcou...
Message Board Posts | Clarus Therapeutics Holdings Inc. Warrant 9/9/2026 (NASDAQ:CRXTW)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Clarus Therapeutics Holdings Inc. Warrant 9/9/2026 Company Name:
CRXTW Stock Symbol:
NASDAQ Market:
NORTHBROOK, Ill., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that it, together with its wholly-owned subsidiary ...
Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million Second quarter 2022 total prescription growth for JATENZO® increased 23% sequentially and increased 72% year-over-year Immediate reduction in workforce by approximately 40% of total headcou...
JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., July 28, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT)...